We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 20, 2020

Targeted NK Cell–Based Adoptive Immunotherapy in NSCLC After Radiochemotherapy

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients With NSCLC After Radiochemotherapy: A Randomized Phase II Clinical Trial
Clin. Cancer Res 2020 Sep 01;[EPub Ahead of Print], G Multhoff, S Seier, S Stangl, et al

Further Reading